TQ-B3525: Clinical Trials

10 trials of TQ-B3525, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 unknown, 1 terminated. 8 Phase 2, 5 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 28Unknown 7, Terminated 1
Phase 15Unknown 4, Terminated 1

Follow TQ-B3525: new trials by email Literature Review of TQ-B3525 trials Research Report on TQ-B3525

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Material Balance Study of TQ-B3525
TQ-B3525 - Chronic Kidney Diseases, Magnetic Resonance Imaging
Phase 1UnknownChia Tai Tianqing Pharmaceutical Group Co., Ltd.82023-01-012023-01-12
A Study of TQ-B3525 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
TQ-B3525 tablets - Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 1 / Phase 2TerminatedChia Tai Tianqing Pharmaceutical Group Co., Ltd.232021-06-052023-11-29
A Study of TQ-B3525 Tablets in Subjects With PIK3CA and/or PIK3R1/2 Gene-altered Recurrent/Metastatic Advanced Gynecologic Tumors
TQ-B3525 tablet - Advanced Endometrial Cancer, Cervical Cancer and Ovarian Cancer
Phase 2UnknownChia Tai Tianqing Pharmaceutical Group Co., Ltd.902021-04-232021-06-01
A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
TQ-B3525 tablets - Diffuse Large B-cell Lymphoma
Phase 2UnknownChia Tai Tianqing Pharmaceutical Group Co., Ltd.932021-01-202021-08-18
A Study of TQ-B3525 in Subjects With Relapsed/Refractory Peripheral T-cell Lymphoma(PTCL)
TQ-B3525 - Peripheral T-cell Lymphoma
Phase 2UnknownChia Tai Tianqing Pharmaceutical Group Co., Ltd.782020-12-012020-11-04
TQB3525 for Advanced Bone Sarcomas With PI3KA Mutations or PTEN Loss
TQB3525 - Safety Issues, Efficacy, Self
Phase 1 / Phase 2UnknownPeking University People's Hospital292020-10-012020-12-31
A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)
TQ-B3525 - Relapsed / Refractory Mantle Cell Lymphoma (MCL)
Phase 2UnknownChia Tai Tianqing Pharmaceutical Group Co., Ltd.1022020-07-202020-09-11
A Study of TQ-B3525 Tablets Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
TQ-B3525, Fulvestrant injection - HR-positive, HER2-negative and PIK3CA Mutation Advanced Breast Cancer
Phase 1 / Phase 2UnknownChia Tai Tianqing Pharmaceutical Group Co., Ltd.422020-07-012020-04-21
A Study of TQ-B3525 in the Treatment of Relapsed / Refractory Follicular Lymphoma (FL)
TQ-B3525 - Relapsed / Refractory Follicular Lymphoma
Phase 2UnknownChia Tai Tianqing Pharmaceutical Group Co., Ltd.802020-05-202020-07-01
A Study of TQ-B3525 on Tolerance and Pharmacokinetics
TQ-B3525 - Relapsed or Refractory Lymphoma or Advanced Cancer
Phase 1UnknownChia Tai Tianqing Pharmaceutical Group Co., Ltd.602018-06-202023-04-14

Conditions studied

Recurrence (2)  ·  Chondrosarcoma (1)  ·  Lymphoma (1)  ·  Lymphoma, Follicular (1)  ·  Lymphoma, Large B-Cell, Diffuse (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Lymphoma, T-Cell, Peripheral (1)  ·  Osteosarcoma (1)  ·  Ovarian Neoplasms (1)  ·  Renal Insufficiency, Chronic (1)  ·  Sarcoma, Ewing (1)  ·  Uterine Cervical Neoplasms (1)

Sponsors

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (9)  ·  Peking University People's Hospital (1)

Countries

China (10)

Top investigators

Huaqing Wang, doctor (1)  ·  Wei Guo, Ph.D and M.D. (1)  ·  Wenqi Jiang, doctor (1)

Results publications

PMID 38627366